TuHURA Biosciences Inc (HURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.467x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.63 Million) by net assets ($18.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TuHURA Biosciences Inc (HURA) total market value for the company's overall valuation and market capitalisation.
TuHURA Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2026)
This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency. See TuHURA Biosciences Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Audio Pixels Holdings Ltd
AU:AKP
|
0.264x |
|
Dongkuk Industries Co. Ltd
KQ:005160
|
0.085x |
|
Actinogen Medical Ltd
AU:ACW
|
-0.507x |
|
Plby Group Inc
NASDAQ:PLBY
|
-0.018x |
|
Song Hong Garment JSC
VN:MSH
|
0.042x |
|
MMP Industries Limited
NSE:MMP
|
0.079x |
|
Super Energy Corporation Public Company Limited
BK:SUPER-R
|
0.082x |
|
Health Catalyst Inc
NASDAQ:HCAT
|
0.186x |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2014–2026)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2014 to 2026. View latest TuHURA Biosciences Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-06-30 | $20.93 Million | $-27.63 Million | -1.320x | -30.79% |
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -113.16% |
| 2024-06-30 | $-1.56 Million | $-11.95 Million | 7.667x | +1356.40% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -30.50% |
| 2014-06-30 | $-817.98K | $-5.52 Million | 6.749x | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more